Skip to content
Blackberry Empire – Lifestyle
Author:
Prime Medicine, Inc.
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
November 12, 2026
Prime Medicine Reports Third Quarter 2026 Financial Results and Provides Business Updates
November 12, 2026
Prime Medicine Announces Pricing of Public Offering of Common Stock
November 10, 2026
Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock
November 10, 2026
Prime Medicine to Present at Jefferies Global Healthcare Conference
November 9, 2026
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
October 5, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
September 24, 2026
Prime Medicine to Participate in Upcoming Investor Conferences
September 3, 2026
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
July 23, 2026
1
2
Next Page
→